Home DNA Damage/DNA Repair PARP inhibitor Rucaparib phosphate

research use only

Rucaparib phosphate PARP inhibitor

Cat.No.S1098

Rucaparib phosphate is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.
Rucaparib phosphate PARP inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 421.36

Jump to

Quality Control

Batch: Purity: 99.88%
99.88

Cell Culture, Treatment & Working Concentration

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BT-474 Function Assay 0.1/1/500/1000 nM inhibits PARP activity at starting concerntration of 500 nM 25128455
BT474 Growth Inhibition Assay 500 nM 10–15 d reduces cell growth in the four lines and significantly 25128455
SKBR3 Growth Inhibition Assay 500 nM 10–15 d reduces cell growth in the four lines and significantly 25128455
AU565 Growth Inhibition Assay 500 nM 10–15 d reduces cell growth in the four lines and significantly 25128455
EFM192A Growth Inhibition Assay 500 nM 10–15 d reduces cell growth in the four lines and significantly 25128455
MDA-MB-231 Function Assay 10/20/40 μM 24 h increases p-AKT levels in a dose-dependent manner 24420152
MDA-MB-231 Cell Viability Assay 0.1-40 μM 24 h IC50 = 17.77 μM 24420152
MDA-MB-231 Apoptosis Assay 10/20/40 μM 24 h induces apoptosis dose dependently 24420152
MDA-MB-231 Growth Inhibition Assay 10/20/40 μM 24 h blocks cell cycle progression in G2/M phase 24420152
H460 Growth Inhibition Assay 400 nM 24 h increases cellular radiosensitivity 24411611
A549  Growth Inhibition Assay 400 nM 24 h increases cellular radiosensitivity 24411611
DT40 Growth Inhibition Assay IC50=21 nM 24356813
DU145 Growth Inhibition Assay IC50=18 nM 24356813
COLO704 Growth Inhibition Assay IC50=2.52 ± 0.67 μM 23729402
OVMANAb Growth Inhibition Assay IC50=2.58 ± 0.38 μM 23729402
OV177 Growth Inhibition Assay IC50=2.78 ± 0.71 μM 23729402
OAW28 Growth Inhibition Assay IC50=3.61 ± 0.28 μM 23729402
OVSAHO Growth Inhibition Assay IC50=3.64 ± 0.33 μM 23729402
OVKATE Growth Inhibition Assay IC50=3.64 ± 1.79 μM 23729402
OVCAR3 Growth Inhibition Assay IC50=3.74 ± 0.40 μM 23729402
PEO14 Growth Inhibition Assay IC50=3.84 ± 0.76 μM 23729402
A2780 Growth Inhibition Assay IC50=3.94 ± 0.25 μM 23729402
OVTOKO Growth Inhibition Assay IC50=4.14 ± 1.53 μM 23729402
KURAMOCHIb Growth Inhibition Assay IC50=4.34 ± 0.29 μM 23729402
TOV21G Growth Inhibition Assay IC50=5.07 ± 1.30 μM 23729402
OVISE Growth Inhibition Assay IC50=5.68 ± 0.23 μM 23729402
KK Growth Inhibition Assay IC50=6.15 ± 1.42 μM 23729402
RMUGS Growth Inhibition Assay IC50=7.03 ± 1.83 μM 23729402
PEO6 Growth Inhibition Assay IC50=7.06 ± 0.74 μM 23729402
OVCA429 Growth Inhibition Assay IC50=8.29 ± 1.64 μM 23729402
OV167 Growth Inhibition Assay IC50=8.33 ± 1.18 μM 23729402
RMG1 Growth Inhibition Assay IC50=9.32 ± 2.36 μM 23729402
OVCAR5 Growth Inhibition Assay IC50=9.50 ± 2.59 μM 23729402
EFO21 Growth Inhibition Assay IC50=9.92 ± 1.87 μM 23729402
ES2 Growth Inhibition Assay IC50=10.12 ± 1.23 μM 23729402
Tyk-nu Growth Inhibition Assay IC50=10.20 ± 1.12 μM 23729402
CAOV3 Growth Inhibition Assay IC50=10.37 ± 0.87 μM 23729402
OV207 Growth Inhibition Assay IC50=12.27 ± 0.32 μM 23729402
HEY Growth Inhibition Assay IC50=13.01 ± 0.75 μM 23729402
DOV13 Growth Inhibition Assay IC50>15 μM 23729402
EFO27 Growth Inhibition Assay IC50>15 μM 23729402
HEY C2 Growth Inhibition Assay IC50>15 μM 23729402
KOC-7cc Growth Inhibition Assay IC50>15 μM 23729402
MCASb Growth Inhibition Assay IC50>15 μM 23729402
OAW42 Growth Inhibition Assay IC50>15 μM 23729402
OV2008 Growth Inhibition Assay IC50>15 μM 23729402
OV90 Growth Inhibition Assay IC50>15 μM 23729402
OVCA420b Growth Inhibition Assay IC50>15 μM 23729402
OVCA432 Growth Inhibition Assay IC50>15 μM 23729402
PEA2 Growth Inhibition Assay IC50>15 μM 23729402
SKOV3 Growth Inhibition Assay IC50>15 μM 23729402
TOV112D Growth Inhibition Assay 0-3 μM IC50>15 μM 23729402
C4-2 Growth Inhibition Assay 0-3 μM 14 d DMSO decreases colony number dose dependently 23565244
PC3 Growth Inhibition Assay 0-3 μM 14 d DMSO decreases colony number dose dependently 23565244
DU145 Growth Inhibition Assay 0-3 μM 14 d DMSO decreases colony number dose dependently 23565244
VCaP  Growth Inhibition Assay 0-3 μM 14 d DMSO decreases colony number dose dependently 23565244
LNCaP  Growth Inhibition Assay 0-3 μM 14 d DMSO decreases colony number dose dependently 23565244
MDA-MB-468 Cell Viability Assay IC50=9.7 μM 22678161
MDA-MB-231 Cell Viability Assay IC50=13 μM 22678161
Cal-51 Cell Viability Assay IC50=8.6 μM 22678161
LoVo Function assay 30 mins Inhibition of PARP in human LoVo cells assessed as inhibition of poly(ADP)-ribose polymerization for 30 mins by fluorescence assay, EC50 = 0.00469 μM. 26652717
MX1 Cytotoxicity assay Cytotoxicity against BRCA1-deficient human MX1 cells, EC50 = 0.0053 μM. 26652717
Rosetta2 (DE3) Function assay Inhibition of human N-terminal 6xhis-tagged ARTD6 (873 to 1161) expressed in Escherichia coli Rosetta2 (DE3) cells using NAD+ as substrate by fluorescence assay, IC50 = 0.014 μM. 24900770
Rosetta2 (DE3) Function assay Inhibition of human 6xhis-tagged ARTD5 (1030 to 1317) expressed in Escherichia coli Rosetta2 (DE3) cells using NAD+ as substrate by fluorescence assay, IC50 = 0.025 μM. 24900770
LoVo Cytotoxicity assay 0.4 uM 5 days Potentiation of temozolomide-induced cytotoxicity in human LoVo cells assessed as temozolomide GI50 at 0.4 uM after 5 days by Celltiter-Glo assay, GI50 = 0.144 μM. 26652717
Capan1 Cytotoxicity assay Cytotoxicity against BRCA2-deficient human Capan1 cells, EC50 = 0.609 μM. 26652717
MDA-MB-436 Anticancer assay 96 hrs Anticancer activity against human BRCA1-deficient MDA-MB-436 cells after 96 hrs by MTT assay, CC50 = 3 μM. 26342868
OVCAR3 Antiproliferative assay 24 hrs Antiproliferative activity against human OVCAR3 cells after 24 hrs by MTT assay, IC50 = 3.31 μM. 29456106
MRC5 Cytotoxicity assay Cytotoxicity against human MRC5 cells, EC50 = 8.53 μM. 26652717
MCF7 Anticancer assay 96 hrs Anticancer activity against human MCF7 cells after 96 hrs by MTT assay, CC50 = 19.47 μM. 26342868
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells 29435139
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 84 mg/mL (199.35 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 421.36 Formula

C19H18FN3O.H3PO4

 Storage (From the date of receipt)
CAS No. 459868-92-9 Download SDF Storage of Stock Solutions

Synonyms AG-014699 phosphate, PF-01367338 phosphate SMILES CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Features
The first PARP inhibitor used in clinical trials combined with temozolomide.
Targets/IC50/Ki
PARP
(Cell-free assay)
1.4 nM(Ki)
In vitro
Rucaparib is a potent inhibitor of purified full-length human PARP-1 and shows higher inhibition of cellular PARP in LoVo and SW620 cells. Besides, Rucaparib binds detectably to eight other PARP domains, including PARP2, 3, 4, 10, 15, 16, TNKS1 and TNKS2. The radio-sensitization by Rucaparib is due to downstream inhibition of activation of NF-κB, and is independent of SSB repair inhibition. Rucaparib could target NF-κB activated by DNA damage and overcome toxicity observed with classical NF-κB inhibitors without compromising other vital inflammatory functions. Rucaparib inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilised D283Med cells.
Kinase Assay
Ki Determination
Inhibition of human full-length recombinant PARP-1 by [32P]NAD+ incorporation is measured. The [32P]ADP-ribose incorporated into acid insoluble material is quantified using a PhosphorImager. Ki is calculated by nonlinear regression analysis.
In vivo
Rucaparib is not toxic but significantly enhances temozolomide-induced TGD in the DNA repair protein-competent D384Med xenografts. Pharmacokinetics studies also show that Rucaparib is detected in the brain tissue, which indicates that Rucaparib has potential in intra-cranial malignancy therapy. Rucaparib significantly potentiates the cytotoxicity of topotecan and temozolomide in NB-1691, SH-SY-5Y, and SKNBE (2c) cells. Rucaparib enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts.
References
  • [4] https://pubmed.ncbi.nlm.nih.gov/20978505/
  • [5] https://pubmed.ncbi.nlm.nih.gov/19174487/

Applications

Methods Biomarkers Images PMID
Western blot PAR BRCA1
S1098-WB1
27960087
Growth inhibition assay Cell viability
S1098-viability1
31119062
Immunofluorescence α-tubulin PAR γH2AX 53BP1
S1098-IF1
30589644

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-29)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03899155 RECRUITING
Cancer
Bristol-Myers Squibb
 2019-08-09 PHASE2
NCT03768063 ACTIVE_NOT_RECRUITING
Cancer
Hoffmann-La Roche
 2019-02-28 PHASE3
NCT02925234 RECRUITING
Cancer; Tumors; Neoplasm; Neoplasia
The Netherlands Cancer Institute
 2016-08 PHASE2
NCT04455750 ACTIVE_NOT_RECRUITING
Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
Alliance for Clinical Trials in Oncology
 2021-10-14 PHASE3
NCT04253262 ACTIVE_NOT_RECRUITING
Metastatic Castration-resistant Prostate Cancer
Brown University
 2020-04-03 PHASE1; PHASE2
NCT04624178 ACTIVE_NOT_RECRUITING
Leiomyosarcoma
Memorial Sloan Kettering Cancer Center
 2020-11-05 PHASE2

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map